Dual Rx Therapy Stalled Pancreatic Cancer
Good news on the pancreatic cancer front has been slow for some time now. But the situation may have changed, as a new study suggests that a combination of two medications may improve the outlook for patients whose pancreatic cancer has spread.
FDA Approves Pancreatic Cancer Treatment
The US Food and Drug Administration today expanded the approved uses of Abraxane (paclitaxel protein-bound particles for injectable suspension, albumin-bound) to treat patients with late-stage (metastatic) pancreatic cancer.
New Life For Advanced Cancer Patients
Gemzar (gemcitabine) is the standard of care for pancreatic cancer. Results from a trial showed that adding another medication worked even better.
Abraxane Shows Positive Progress for Pancreatic Cancer Treatment
Celgene International Sàrl, a subsidiary of Celgene Corporation today announced that its phase III study of Abraxane (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in treatment-naïve patients with advanced pancreatic cancer met its primary endpoint of overall survival.
Dual Therapies for Treating Pancreatic Cancer
Currently, there's only one chemotherapy agent being used to treat pancreatic cancer. Gemzar (gemcitabine) works for some patients, but not others.